Not Reddy for Lamisil
This article was originally published in The Tan Sheet
Indian pharma firm Dr. Reddy's withdraws from patent battle with Novartis over prescription oral toenail fungus treatment Lamisil Tablets (terberafine hydrochloride), the firms announce Sept. 3. Under a consent judgment in Manhattan federal court, Reddy's may not manufacture, use, sell or import into the U.S. a generic version at least until Novartis' patent expires in December 2006 (or six months later, if pediatric exclusivity is granted). Reddy's will not pursue the challenge further and will amend its ANDA from Paragraph IV to Paragraph III. Both parties "have dismissed all pending claims," closing out a suit initiated by Novartis in July 2002...
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.
Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.